4//SEC Filing
Cheng Sohanya Roshan 4
Accession 0000950170-25-032323
CIK 0001503802other
Filed
Mar 3, 7:00 PM ET
Accepted
Mar 4, 4:54 PM ET
Size
11.8 KB
Accession
0000950170-25-032323
Insider Transaction Report
Form 4
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Transactions
- Award
Common Stock
2025-02-28+5,416→ 33,176 total - Award
Stock Option (right to buy)
2025-02-28+10,833→ 10,833 totalExercise: $7.95Exp: 2035-02-27→ Common Stock (10,833 underlying) - Award
Common Stock
2025-02-28+4,583→ 37,759 total - Award
Stock Option (right to buy)
2025-02-28+9,166→ 9,166 totalExercise: $7.95Exp: 2035-02-27→ Common Stock (9,166 underlying)
Footnotes (5)
- [F1]Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2026.
- [F2]Amounts reported in this Form 4 reflect the one-for-fifteen reverse stock split effected by the Issuer on February 25, 2025.
- [F3]Includes 824 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2022 Employee Stock Purchase Plan on October 31, 2024.
- [F4]Represents the award of RSUs pursuant to the 2022 Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in two equal annual installments beginning February 28, 2026.
- [F5]This option was granted on February 28, 2025 pursuant to the 2022 Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
Karyopharm Therapeutics Inc.
CIK 0001503802
Entity typeother
Related Parties
1- filerCIK 0001865796
Filing Metadata
- Form type
- 4
- Filed
- Mar 3, 7:00 PM ET
- Accepted
- Mar 4, 4:54 PM ET
- Size
- 11.8 KB